Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.

Published

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Raghu, G; Collard, HR; Anstrom, KJ; Flaherty, KR; Fleming, TR; King, TE; Martinez, FJ; Brown, KK

Published Date

  • June 1, 2013

Published In

Volume / Issue

  • 187 / 11

Start / End Page

  • 1272 -

PubMed ID

  • 23725623

Pubmed Central ID

  • 23725623

Electronic International Standard Serial Number (EISSN)

  • 1535-4970

Digital Object Identifier (DOI)

  • 10.1164/rccm.201304-0712LE

Language

  • eng

Conference Location

  • United States